Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer

被引：13
|
作者：
Devlies, Wout [1 ,2 ]
Eckstein, Markus [3 ]
Cimadamore, Alessia [4 ]
Devos, Gaetan [1 ]
Moris, Lisa [1 ,2 ]
van den Broeck, Thomas [1 ]
Montironi, Rodolfo [4 ]
Joniau, Steven [1 ]
Claessens, Frank [2 ]
Gevaert, Thomas [5 ]
机构：
[1] Univ Hosp Leuven, Dept Urol, B-3000 Leuven, Belgium
[2] Katholieke Univ Leuven, Lab Mol Endocrinol, B-3000 Leuven, Belgium
[3] Friedrich Alexander Univ Erlangen Nurnberg, Dept Pathol, D-91054 Erlangen, Germany
[4] Polytech Univ theMarche Reg, United Hosp, Sch Med, Sect Pathol Anat, I-60121 Ancona, Italy
[5] Univ Hosp Leuven, Dept Pathol, B-3000 Leuven, Belgium
来源：
CELLS | 2020年 / 9卷 / 11期
关键词：
prostate cancer; biomarker; targeted therapies; histology; mCRPC; androgen receptor; ANDROGEN-DEPRIVATION THERAPY; CIRCULATING TUMOR-CELLS; POZ PROTEIN SPOP; EMERGING MECHANISMS; RECEPTOR; EXPRESSION; MUTATIONS; GENE; TMPRSS2-ERG; INHIBITORS;
D O I：
10.3390/cells9112494
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
The development of targeted therapies increases treatment options for metastatic castration resistant prostate cancer (mCRPC) patients. There is a need for strong predictive and prognostic signatures to guide physicians in treating mCRPC patients. In this review we unravel the possible actionability in the AR pathway, PI3K AKT signaling, and DNA repair pathways. Additionally, we make recommendations on biomarker trial design, and the clinical use of this new type of data.
引用
收藏
页码：1 / 13
页数：13
相关论文
共 50 条
  • [11] Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians
    Merseburger, Axel S.
    Waldron, Nick
    Ribal, Maria J.
    Heidenreich, Axel
    Perner, Sven
    Fizazi, Karim
    Sternberg, Cora N.
    Mateo, Joaquin
    Wirth, Manfred P.
    Castro, Elena
    Olmos, David
    Petrylak, Daniel P.
    Chowdhury, Simon
    EUROPEAN UROLOGY, 2021, 79 (04) : 519 - 529
  • [12] Chemotherapy in metastatic castration resistant prostate cancer
    Rosino, Antonio
    Ballester, Inmaculada
    Tudela, Julian
    Gonzalez-Billalabeitia, Enrique
    ARCHIVOS ESPANOLES DE UROLOGIA, 2018, 71 (08): : 676 - 684
  • [13] Single cell-transcriptomic analysis informs the lncRNA landscape in metastatic castration resistant prostate cancer
    Saha, Debanjan
    Dang, Ha X.
    Zhang, Meng
    Quigley, David A.
    Feng, Felix Y.
    Maher, Christopher A.
    NPJ GENOMIC MEDICINE, 2024, 9 (01)
  • [14] The Natural History and Outcome Predictors of Metastatic Castration-resistant Prostate Cancer
    van Soest, Robert J.
    Efstathiou, Jason A.
    Sternberg, Cora N.
    Tombal, Bertand
    EUROPEAN UROLOGY FOCUS, 2016, 2 (05): : 480 - 487
  • [15] Editorial: Metastatic Castration Resistant Prostate Cancer: Prognosis and Treatment
    Muniyan, Sakthivel
    Li, Benyi
    Batra, Surinder K.
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [16] Monitoring of treatment for metastatic castration-resistant prostate cancer
    Hinz, Stefan
    AKTUELLE UROLOGIE, 2017, 48 (03) : 225 - 229
  • [17] Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
    Henriquez, Ivan
    Roach, Mack I. I. I. I. I. I.
    Morgan, Todd M.
    Bossi, Alberto
    Gomez, Junior A.
    Abuchaibe, Oscar
    Counago, Felipe
    BIOMEDICINES, 2021, 9 (09)
  • [18] Perspectives on Treatment of Metastatic Castration-Resistant Prostate Cancer
    Merseburger, Axel S.
    Bellmunt, Joaquim
    Jenkins, Cheryl
    Parker, Chris
    Fitzpatrick, John M.
    ONCOLOGIST, 2013, 18 (05): : 558 - 567
  • [19] Transcriptome Profiling of Circulating Tumor Cells to Predict Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer
    Groen, Levi
    Kloots, Iris
    Englert, David
    Seto, Kelly
    Estafanos, Lana
    Smith, Paul
    Verhaegh, Gerald W.
    Mehra, Niven
    Schalken, Jack A.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (10)
  • [20] A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer
    Seisen, Thomas
    Roupret, Morgan
    Gomez, Florie
    Malouf, Gabriel G.
    Shariat, Shahrokh F.
    Peyronnet, Benoit
    Spano, Jean-Philippe
    Cancel-Tassin, Geraldine
    Cussenot, Olivier
    CANCER TREATMENT REVIEWS, 2016, 48 : 25 - 33
12345